Kornimate/medical-research-clean huggingface dataset:
examining the effects of (mim) treatment on emotional and cognitive functioning of residents in long-term care

Conditions: Emotion; Impaired Cognition

Summary: to examine the effects of a music, imagery, and movement (mim) intervention on emotional and cognitive functioning in residents living in a community-based adult long-term care facility. hypothesis 1: residents who participate in the mim group will improve in emotional functioning, as compared to residents in the control group. hypothesis 2: residents who participate in the mim group will improve in cognitive functioning, as compared to residents in the control group.

to implement a community-based integrated music, art and imagery, and movement intervention to improve mood and promote cognitive functioning in older adult residents living in a long-term care facility.

Eligibility criteria:
inclusion criteria: * resident in assisted living at long-term care facility with mmse score above 20 exclusion criteria: * co-morbid psychiatric diagnosis and/or staff clinical evaluation that determines inappropriateness for study inclusion

Keywords: creative arts older adults intervention study
effectiveness of contemporary knee arthroplasty in working-age patients

Conditions: Knee Osteoarthritis

Summary: the aim of our study was to assess the effectiveness of contemporary knee arthroplasty in working-age patients (\< 65 years) by conducting a prospective cohort study with 2-year follow up. outcomes were measured comprehensively using various patient-reported outcome measures (proms) to provide information on the effect of knee arthroplasty on pain, satisfaction, physical activity, activities of daily living, and quality of life.


Eligibility criteria:
inclusion criteria: * age 65 or less and * scheduled for either tka or unicondylar knee arthroplasty (uka) exclusion criteria: * rheumatoid arthritis or other inflammatory diseases * unwilling to provide informed consent * physical, mental, or neurological conditions that could comprise the patient´s ability and compliance with postoperative rehabilitation and follow-up (e.g., drug or alcohol abuse, serious mental illness, general neurological conditions such as parkinson's disease, multiple sclerosis (ms), etc.) * known sensitivity to materials in the devices.

Keywords: knee arthroplasty working-age patient related outcome measures
ecg belt for crt response

Conditions: Heart Failure

Summary: the purpose of this clinical study is to compare ecg belt research system managed cardiac resynchronization therapy (crt) patients and a control crt group with respect to left ventricular (lv) remodeling.

the ecg belt study is a prospective, interventional, randomized, multi-center, investigational, pre-market research study. the ecg belt research system will be used at implant and follow-up to help implanters choose a suitable lv pacing site within the recommended locations for lv lead implantation and optimize pacing vector/timing parameters.

Eligibility criteria:
inclusion criteria: * indicated for crt, with qrs duration ≥130 ms, and planned to be implanted with a market-released medtronic crt device with adaptivcrt and a medtronic quadripolar lv lead. * meets at least one of the following criteria: qrs duration \< 150 ms, prior documented myocardial infarction, non-lbbb * lvedd ≥ 55 mm, as determined by site exclusion criteria: * permanent/persistent af or presenting with af * pre-existing or previous lv lead or other confounding devices e.g. left ventricular assist device, vagal nerve stimulator * currently implanted with ipg or icd with \> 10% rv pacing * permanent complete av block * enrolled in a concurrent study that may confound the results of this study. pre-approval from the study manager is required for enrollment of a patient that is in a concurrent study. * less than 1 year life expectancy * vulnerable adults * younger than 18 years of age
modified anterior lamellar recession for all grades of upper eyelid trachomatous cicatricial entropion

Conditions: Entropion

Summary: this study aims to assess the combination of anterior lamellar recession (alr) with blepharoplasty, suprasternal fixation, and internal eyelash bulb extirpation of aberrant lashes posteriorly located in patients with any grade of upper eyelid trachomatous cicatricial entropion


Eligibility criteria:
inclusion criteria: * all patients presented with upper lid trachomatous cicatricial entropion associated with rubbing lashes. * patients having a history of argon laser ablation, electrolysis, epilation, or past unsuccessful surgery were also included exclusion criteria: * patients with a follow-up period of fewer than 12 months. * patients with very severe uce and required posterior lamellar grafts. * patients with etiology other than trachoma. * patients with dysplastic lashes without entropion were excluded
exploratory assessment of the effects of cyclo 3 ® fort (ruscus extract, hesperidin methyl chalcone, ascorbic acid) or micronised purified flavonoid fraction on vascular parameters and biomarkers in women suffering from chronic venous disease (ceap c2 or c3), over 8 weeks

Conditions: Venous Disease Classification (CEAP): C2 or C3

Summary: chronic venous disorder is the most prevalent vascular disease. it is multifactorial pathology that has an important impact on quality of life and represents a significant public health concern, due to its very high frequency in all european and american (north and south) countries. venous pathology develops when venous pressure is increased and return of blood is impaired through several mechanisms. wish induce leg symptoms (tingling, aching, burning, pain, muscle cramps, sensation of swelling, sensations of throbbing or heaviness, itching skin, restless legs, leg tiredness and/or fatigue. the aims of this research is to study the effects on microcirculatory activity (activity on very small vessels) of cyclo 3 ® fort, mpff (micronised purified flavonoid fraction) and placebo after 8 week of treatment by microscan, and duplex, two imaging non-invasive technologies will be performed to obtain measurements of microcirculatory parameters in standardized and reproducible conditions for all the participants. in addition, will assess, in blood samples, the inflammatory biomarkers .


Eligibility criteria:
inclusion criteria: 1. inclusion criteria * non-menopausal women aged from 18 to 50 years * symptomatic primary chronic disorder c2 or c3 of advanced ceap * regular menstrual cycle * use an efficient method of contraception * having signed her written informed 2. non-inclusion criteria 2.1 related to pathology: * superficial and or deep venous thrombosis * venous insufficiency including history of deep venous thrombosis, post thrombotic syndrome, venous dysplasia, compressive syndrome * history of venous strapping or phlebotomy/ surgery of the evaluated leg * sclerosing injection within 6 month before inclusion * oedema from other etiology * paresthesia, cramps of the lower limbs from other origin 2.2 related to treatment: * hypersensitivity, allergy or intolerance to study drugs * iron storage disorder * intake of venotonic treatment (oral or topic) ,triptan ,diuretics ,calcium blockers, beta blockers, ace inhibitors, angiotensine ii inhibitors, vasodilatators and/or vasoconstrictors within 1 month before inclusion * intake of nsaid,corticosteroids,ergotamine, dihydroergotamine or any ergot alkaloids,vitamin c nutraceutical or phytotherapy products with potential venotonic effect within 2 weeks before inclusion 2.3 related to the population: * history of diabetes * bmi≥ 30 * grade v and vi on fitzpatrick classification
airway hyper-responsiveness study in asthma using salmeterol/fluticasone propionate combination product

Conditions: Asthma

Summary: this double-blind, stratified, parallel group study is to determine whether aiming for 'total control' results in better airway hyper-responsiveness than maintaining the treatment level at which 'well-controlled' asthma was achieved. the primary endpoint is the mean change in pc20 methacholine. well controlled subjects (as assessed after a 12 week run-in period) will enter a 24 week treatment period during which they will record pef(peak expiratory flow), symptoms, rescue beta2-agonist use over 24 hours, night time awakenings, asthma exacerbations, emergency visits due to asthma and adverse events. at every visit lung function measurements and airway hyper-responsiveness will be measured.

a multi-centre, randomised, double blind, stratified, and parallel group study to evaluate whether a treatment strategy based on aiming for 'total control' results in better airway hyper-responsiveness than a treatment strategy based on maintaining the treatment level at which 'well-controlled' asthma was achieved.

Eligibility criteria:
inclusion criteria: * history of asthma of at least 6 months. * subjects who have received fluticasone propionate at a dose of 100 mcg bd to 250 mcg bd or equivalent with or without a long acting beta2-agonist for at least 4 weeks before the start of the run-in period, at a constant dose. * subjects who are able to understand and complete an electronic diary card. exclusion criteria: * subjects who have been hospitalized for their asthma within 4 weeks of study entry. * subjects who had an acute upper respiratory tract infection within 4 weeks or a lower respiratory tract infection within 4 weeks prior to study entry. * subjects who received oral, parental or depot corticosteroids within 4 weeks prior to study entry. * subjects who have a known respiratory disorder other than asthma and/or systemic/thoracic abnormalities which influence normal lung function. * subjects who have more than 5 pack years. * subjects who currently smoke.

Keywords: total asthma control airway hyper-responsiveness adult asthma
curative effect evaluation of danlou tablet on coronary artery disease not amenable to revascularization

Conditions: Coronary Artery Disease(CAD)

Summary: the purpose of this study is to determine whether danlou tablet is effective in the treatment of coronary artery disease not amenable to revascularization on the basis of western medicine therapy.

the western medicine treatment for cad not amenable to revascularization is limited. danlou tablet, a kind of chinese patent medicine has been used for treating coronary artery disease in clinical practice in china for many years. danlou tablet is applicable to "phlegm-stasis syndrome" in traditional chinese medicine. according to recent studies, danlou tablet can reduce blood lipid level and myocardial necrosis area ,promote infarct healing in rats.and it can improve clinical symptoms of patients with cad.

Eligibility criteria:
inclusion criteria: * participants are aged between 45 and 75 years, diagnosed with sever cad through coronary arteriography which shows that the left main coronary artery and three-vessel have sever diffuse stenosis, calcification or vascular ectasia, be in accordance with traditional chinese medicine syndrome of "qi deficiency and blood stasis syndrome" or "phlegm and stasis mu-tual obstruction syndrome". exclusion criteria: * patients with severe valvular disease, congenital cardiomyopathy decompensation * patients with cad complicated with severe multiple organ disease such as severe heart failure, severe lung, liver or renal dysfunction, peptic ulcer in active stage, or intracranial hemorrhage * patients that use high-dose steroids due to connective tissue disease * patients with serious infections * patients with malignant tumor * patients with hematopoietic diseases * pregnant or lactating women.

Keywords: coronary artery disease revascularization danlou tablet
telemedicine for prep throughout mississippi

Conditions: HIV/AIDS

Summary: this study will develop and test a program to deliver prep care in underserved communities in mississippi (ms) through telemedicine, distance-based, clinical care delivered in local community based organizations (cbos). the intervention will be developed in collaboration with medical specialists at the university of mississippi medical center (ummc) and local cbo stakeholders (providers, administrators and patients). approximately 75 individuals will be recruited from cbos in ms. participants will be able to receive prep counseling in the cbo and prep care via telemedicine from a prep specialist at ummc. participants will complete three assessments in the six months after enrolling. our study will provide a wealth of information about prep-related outcomes and hiv testing among ms residents living in underserved communities. if successful, this program will be able to be disseminated to other cbos in the south.

uptake of prep in the southern united states has been slow, especially in areas distant from academic medical centers that provide prep care. despite underserved populations in the south having alarmingly high rates of hiv, a large percentage of at-risk individuals are not engaged in prep care due to limited access to academic medical centers. mississippi (ms), the site of this proposed project, has the seventh highest incidence of hiv of any state and cbos that provide hiv/sti testing outside of urban areas report that very few of their at-risk individuals use prep. unfortunately, physicians outside of academic centers are often reluctant to prescribe prep because they lack the expertise, training, and the support necessary to provide comprehensive hiv prevention care. those are at-risk do not seek prep from academic centers because of stigma, travel burdens, and financial concerns. to overcome these barriers, this project will develop and pilot test a program to deliver prep care in underserved remote communities in ms through telemedicine clinical care delivered in local cbos. telemedicine will allow specialists to provide care at a distance and while simultaneously enhancing the capacity of local cbos to provide quality hiv testing and counseling, prep treatment, and linkage to hiv care if needed. it will allow patients to receive the highest level of medical care from trusted cbos within their local communities. it will also enhance the cbo's mission by allowing it to provide a new, high-quality medical service.

Eligibility criteria:
inclusion criteria: * 18 years old or older * presented at a collaborating cbo for hiv testing during trial months * prep eligible based on hiv risk checklist * able to read and speak english * able to give meaningful consent as determined by research staff * no known hiv infection exclusion criteria: * none
postprandial fatty acid metabolism in the natural history of type 2 diabetes (t2d)

Conditions: Impaired Glucose Tolerance

Summary: lipotoxicity-causing fatty acid overexposure and accretion in lean tissues leads to insulin resistance and impaired pancreatic β-cell function - the hallmarks of t2d - contributing to associated complications such as heart failure, kidney failure and microvascular diseases. proper dietary fatty acid (dfa) storage in white adipose tissue (wat) is now thought to prevent lean-tissue lipotoxicity. using novel positron-emission tomography (pet) and stable isotopic tracer methods which were developed in sherbrooke, the investigator showed that wat storage of dfa is impaired in people with pre-diabetes or t2d. the investigator also showed that this impairment is associated with greater cardiac dfa uptake, as well as subclinical left-ventricular systolic and diastolic dysfunction. then, it has been found that modest weight loss in pre-diabetics, after a one-year lifestyle intervention, improved wat dfa storage, curbed cardiac dfa uptake, and restored associated left-ventricular dysfunction. it has been also found that a 7-day low-saturated fat, low-calorie diet raised insulin sensitivity but did not restore wat or cardiac dfa metabolism. whether wat dfa storage directly impacts cardiac dfa uptake is not known. importantly, the investigator recently uncovered marked sex-specific differences in wat dfa metabolism. these may explain, at least in part, sex-related differences in the cardiac dfa uptake, which occurs in pre-diabetes. higher spillover of wat dfa into circulating non-esterified fatty acid (nefa) appears to be linked in women to greater cardiac dfa uptake, as opposed to direct cardiac chylomicron triglycerides (tg) uptake in men. here, the investigator will isolate and compare organ-specific fatty acid uptake occurring postprandially from chylomicron-tg vs. nefa pools, as well as the oxidative vs. non-oxidative intracellular metabolic pathways associated with increased cardiac dfa uptake in pre-diabetic men and women.


Eligibility criteria:
inclusion criteria: * for healthy subjects: fasting glucose \< 5.6, 2-hour post 75g oral glucose tolerance test (ogtt) glucose \< 7.8 mmol/l and hba1c \< 5.8% * for subject with glucose intolerance (igt): 2-hour post 75g ogtt glucose at 7.8-11.1 mmol/l on two separate occasions and hba1c of 6.0 to 6.4% exclusion criteria: * overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ecg * treatment with a fibrate, thiazolidinedione, beta-blocker or other drug known to affect lipid or carbohydrate metabolism (except statins, metformin, and other antihypertensive agents that can be safely interrupted) * presence of liver or renal disease, uncontrolled thyroid disorder, previous pancreatitis, bleeding disorder, or other major illness * smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day * prior history or current fasting plasma cholesterol level \> 7 mmol/l or fasting tg \> 6 mmol/l * any other contraindication to temporarily interrupt current meds for lipids or hypertension * being pregnant * not be barren
comparison between different doses of steroids in covid-19 patients

Conditions: Critical Illness; Pneumonia, Viral

Summary: aim of this study is to compare between standard dose methyl prednisolone and mega dose methyl prednisolone as regards outcome reflected by mortality rate, percentage of mechanically ventilated patients and icu length of stay of covid 19 patients admitted in intensive care unit.

retrospective study for comparison between standard dose methyl prednisolone and mega dose methyl prednisolone as regards outcome reflected by mortality rate ,percentage of mechanically ventilated patients and icu length of stay of covid 19 patients admitted in intensive care unit. previous studies suggested that cytokine release syndrome could be involved in the pathophysiology of critical sars.cov.2 resulting in death so early suppression of cytokine storm may be lifesaving in critical patients.

Eligibility criteria:
inclusion criteria: * all icu admitted covid 19 patients with positive pcr, diagnosed by ct chest and needing oxygen therapy exclusion criteria: * not requiring oxygen therapy * negative pcr * uncontrolled blood sugar or dka * patients on long term steroids therapy
transdermal patch to monitor inflammatory biomarkers of gvhd

Conditions: Graft Versus Host Disease

Summary: the aim of this study is to measure local inflammatory responses in patients undergoing an allogeneic stem cell transplant and attempt to define any set of biomarkers that are significantly altered in acute or chronic skin graft versus host disease.

acute skin graft versus host disease is a significant complication following allogeneic stem cell transplant. to date, there are no specific dermal biomarkers that predict or define the onset of acute skin graft versus host disease. the primary objective of this study is to observe the changes in the inflammatory environment of the skin during the process of acute and chronic skin graft versus host disease. this will be accomplished by using a non-invasive transdermal patch called d-squame to analyze inflammatory cytokines and key epidermal proteins. patients will be enrolled prior to receiving a stem cell transplant and followed weekly after stem cell infusion until day 99. if acute skin graft versus host disease develops, they will be followed weekly until resolution of acute graft versus host disease or development of chronic graft versus host disease, whichever occurs first. patients with a diagnosis of chronic skin graft versus host disease will be enrolled and followed weekly until 4 weeks, irrespective of clinical course. in addition, healthy controls will be enrolled and used as comparators. the relevance of this study is to provide a better understanding of the local inflammatory environment induced by acute or chronic skin graft versus host disease. this is likely to enable the investigators to define a biomarker panel that predicts the onset of acute graft versus host disease rapidly and non-invasively.

Eligibility criteria:
inclusion criteria for patients who may develop acute graft versus host disease: * all patients undergoing an allogeneic hematopoietic stem cell transplant at cchmc. * all conditioning regimens are eligible. exclusion criteria for patients who may develop acute graft versus host disease: • pre-existing skin conditions like, but not limited to epidermolysis bullosa, psoriasis, acne, or cellulitis. inclusion criteria for patients who have chronic graft versus host disease: * bone marrow transplant performed at cchmc or an outside institution. * diagnosis of chronic skin graft versus host disease. exclusion criteria for patients who have chronic graft versus host disease: • bone marrow transplant performed for epidermolysis bullosa. inclusion criteria for controls: * healthy volunteers. * age matched to the patients with existing acute skin graft versus host disease. exclusion criteria for controls: • pre-existing dermatologic conditions. (e.g. eczema, psoriasis, acne etc.)

Keywords: children bone marrow transplant gvhd
determining the effect of actimmune (interferon gamma 1b)dose titration on flu-like symptoms in healthy volunteers

Conditions: Adverse Effects in the Therapeutic Use of Interferon

Summary: the most frequent side effects associated with actimmune (interferon gamma 1b) therapy are the occurrence of 'flu-like symptoms' (fls),which might include fever, chills, muscle aches, and tiredness. earlier studies have demonstrated that these symptoms are common in healthy volunteers as well as in patients. this study is designed to determine whether a titration of dosing reduces the frequency and severity of the fls. a reported study with another interferon (interferon beta), demonstrated a reduction in the frequency and severity of the fls when a titration of dosing was used. this study will compare the effects of the standard dose regimen with a titration regimen in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy volunteers * ability to understand purpose \& risks * bmi 18-32kg/m2 * females on contraception exclusion criteria: * history of hiv,or pos test for hcv ab,or hbsag * history of chronic fatigue syndrome or fibromyalgia * flu like illness within 1 month of start * history of depression or other mood disorder * history of malignant or pre-malignant disease * history of severe allergic reactions * known allergy to actimmune or its components * history of major diseases * clinically significant abnormal labs * pregnant or breastfeeding * clinically abnormal ecg * history of alcohol or substance abuse * other study participation in last 4 weeks * serious infection within 3 months * use of rx products within 4 weeks except contraceptives or dermatology products * vaccinations within 2 weeks * tobacco products ( with limitations) * cant/wont comply with study requirements * allergy shots within 1 month * blood donation with limitations * investigator discretion as to unsuitability

Keywords: dose titration fls flu like symptoms actimmune